Rise in GLP-1 RA and SGLT2 Inhibitor Prescribing in Patients With T1D

Diabetes Mellitus Type 1 News

Rise in GLP-1 RA and SGLT2 Inhibitor Prescribing in Patients With T1D
Diabetes Mellitus Type IType 1 DiabetesType 1 DM
  • 📰 Medscape
  • ⏱ Reading Time:
  • 15 sec. here
  • 19 min. at publisher
  • 📊 Quality Score:
  • News: 68%
  • Publisher: 55%

An analysis of over 400,000 patients with T1D revealed a rise in prescribing for glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors over the past decade.

Increases in prescriptions for both glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors were observed in patients with type 1 diabetes from 2010 to 2023.GLP-1 RAs and SGLT2 inhibitors have significant benefits in cardiorenal protection and weight management; however, these medications are currently not approved for patients with T1D .

A well-validated EHR-based algorithm was used to identify patients with T1D while removing duplicates. The percentage of patients with T1D prescribed GLP-1 RAs increased from 0.3% in 2010 to 6.6% by 2023 and SGLT2 inhibitors increased from 0.1% to 2.4% over the same period.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

Medscape /  🏆 386. in US

Diabetes Mellitus Type I Type 1 Diabetes Type 1 DM T1DM T1D SGLT2 Inhibitors Sodium-Glucose Transporter-2 Inhibitors Sodium-Glucose Co-Transporter-2 Inhibitors Sodium-Glucose Cotransporter-2 Inhibitors Diabetes Mellitus Type 2 Diabetes Mellitus Type Ii Type 2 Diabetes Type 2 DM T2DM T2D GLP-1 Receptor Agonists Glucagon-Like Peptide-1 Receptor Agonists

United States Latest News, United States Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

The Rise of Unregulated 'Peptide Companies' Amidst GLP-1 Drug ShortageThe Rise of Unregulated 'Peptide Companies' Amidst GLP-1 Drug ShortageAs demand for brand-name injectable weight loss drugs like Ozempic and Wegovy skyrockets, the market is flooded with unregulated peptide companies selling knockoff versions of these medications. This article explores the dangers associated with these unapproved products and examines the efforts being made to address the shortage of legitimate GLP-1 drugs.
Read more »

CGM With Geriatric Care Simplifies T1D Management in SeniorsCGM With Geriatric Care Simplifies T1D Management in SeniorsContinuous glucose monitoring enhanced by geriatric care principles reduced the duration of hypoglycemia without worsening glycemic control in older adults with T1D.
Read more »

First Patient-Derived Stem Cell Transplant a Success in T1DFirst Patient-Derived Stem Cell Transplant a Success in T1DAt 1 year, islets chemically reprogrammed from the patient's own somatic cells allowed them to become insulin-independent with the use of immunosuppression.
Read more »

Young Adults With T1D Benefit from Tailored Support ProgramYoung Adults With T1D Benefit from Tailored Support ProgramA support program tailored to the needs of young adults with T1D was found to reduce hospitalizations and improve glycemic control when compared with usual endocrine care.
Read more »

Urinary Calcium: A Marker of Bone Health in Youth With T1D?Urinary Calcium: A Marker of Bone Health in Youth With T1D?Greater urinary calcium excretion was associated with reduced bone accrual in youth with type 1 diabetes, found an observational study.
Read more »

T2D More Prevalent Than T1D Among Adolescents in Some AreasT2D More Prevalent Than T1D Among Adolescents in Some AreasAdolescents with type 2 diabetes have a higher incidence of complications than adults with type 2 diabetes or adolescents with type 1 diabetes.
Read more »



Render Time: 2025-02-12 13:01:15